Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, Thomas, Chase, Andrew J, Score, Joannah, Hidalgo-Curtis, Claire E, Bryant, Catherine, Jones, Amy V, Waghorn, Katherine, Zoi, Katerina +10 more·2010·Nature Genetics
DOI 10.1038/ng.621

Cited by (1,000)

Items 801–900 of 1,000

  1. Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment
    Xiaohui Zhang, Jeffrey E. Lancet, Ling Zhang · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
  2. Epigenetic deregulation in myeloid malignancies
    Kristen M. Meldi, María E. Figueroa · 2014 · Translational research
  3. Alterations of Histone Modifications in Cancer
    Ciro Mercurio, Simon Edward Plyte, Saverio Minucci · 2012 · Elsevier eBooks
  4. Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles
    Xinan Holly Yang, Bin Wang, John M. Cunningham · 2015 · BMC Medical Genomics
  5. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications
    Luca Malcovati, Ilaria Ambaglio, Chiara Elena · 2015 · Current Opinion in Oncology
  6. EZH2: a pleiotropic protein
    Thomas Burmeister · 2016 · Blood
  7. High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis
    Kimihito Cojin Kawabata, Yasutaka Hayashi, Daichi Inoue, H Meguro, Hiroko Sakurai, Tomofusa Fukuyama, Yosuke Tanaka, Shuhei Asada, T Fukushima, Reina Nagase et al. · 2017 · Leukemia
  8. Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia
    Aishu Dong, Wen‐Bin Yang, He Feng Huang, Xiaohai Zhou, Zhewei He, Rongxing Yao, Wenjian Guo · 2020 · Oncology Reports
  9. From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes
    Macoura Gadji, Aline Rangel Pozzo · 2018 · Genes Chromosomes and Cancer
  10. Drug Discovery Methods
    Marie Lopez, Maxime Leroy, Chantal Etiévant, Fréderic Ausseil, Alexandre Gagnon, Paola Barbara Arimondo · 2016 · Elsevier eBooks
  11. Genetic Determinants of Cancer Susceptibility
    Joe M. Angel, Erika L. Abel, John DiGiovanni · 2010 · Elsevier eBooks
  12. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition
    Lilia Falkenstern, Victoria Georgi, Stefanie Bunse, Volker Badock, Manfred Husemann, Ulrike Roehn, Timo Stellfeld, Mark E. Fitzgerald, Steven J. Ferrara, Detlef Stöckigt et al. · 2024 · Scientific Reports
  13. Myeloid sarcoma shows a high frequency of mutations activating the MAPK / ERK pathway and association with clonal hematopoiesis
    Dominik Nann, Tim‐Colin Schade, Mathis Overkamp, Lejla Mahmutovic, Eyyub Bag, Stephan Forchhammer, Julia Slotta‐Huspenina, L Boudová, Karl Sotlar, Leticia Quintanilla‐Martínez et al. · 2025 · The Journal of Pathology Clinical Research
  14. Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies
    Ashot S. Harutyunyan, Bettina Gisslinger, Thorsten Klampfl, Tobias Berg, Klaudia Bagienski, Heinz Gisslinger, Róbert Královics · 2011 · Leukemia
  15. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes
    Meaghan Wall · 2016 · Methods in molecular biology
  16. Epigenetics
    Rosanna Weksberg, Darci T. Butcher, Daria Grafodatskaya, Sanaa Choufani, Benjamin Tycko · 2013 · Elsevier eBooks
  17. Knockdown of NIR Suppresses Breast Cancer Cell Proliferation via Promoting FOXO3
    Bolin Chen, Chengcheng Dong, Fang Wang, Jiacai Wu · 2021 · OncoTargets and Therapy
  18. Oncogenic Roles of Polycomb Repressive Complex 2 in Bladder Cancer and Upper Tract Urothelial Carcinoma
    Eric Yi‐Hsiu Huang, Yu-Kuang Chen, Chen-Pu Ou, Yi‐Ting Chen, Sung‐Fang Chen, William J. Huang, Kung‐Hao Liang · 2022 · Biomedicines
  19. Biological Functions of the KDM2 Family of Histone Demethylases
    Jaclyn Andricovich, Alexandros Tzatsos · 2023 · Advances in experimental medicine and biology
  20. Polycomb group proteins in hematopoietic stem cell aging and malignancies
    Karin Klauke, Gerald de Haan · 2011 · International Journal of Hematology
  21. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations
    Jean-Noël Bastie, Romain Aucagne, Nathalie M Droin, Éric Solary, Laurent Delva · 2012 · Cellular and Molecular Life Sciences
  22. Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup
    Elena Ciabatti, Angelo Valetto, Veronica Bertini, Maria Immacolata Ferreri, Alice Guazzelli, Susanna Grassi, Francesca Guerrini, Iacopo Petrini, Maria Rita Metelli, Maria Adelaide Caligo et al. · 2017 · Oncotarget
  23. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes
    Naoyuki Kataoka, Eri Matsumoto, So Masaki · 2021 · International Journal of Molecular Sciences
  24. One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
    Antonia Kalushkova, Patrick Nylund, Alba Atienza Párraga, Andreas Lennartsson, Helena Jernberg‐Wiklund · 2021 · Epigenomes
  25. Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID‐19
    Seyedeh Hoda Alavizadeh, Maham Doagooyan, Fatemeh Zahedipour, Shima Yahoo Torghabe, Bahare Baharieh, Firooze Soleymani, Fatemeh Gheybi · 2022 · IET Nanobiotechnology
  26. Switch-Independent 3A: An Epigenetic Regulator in Cancer with New Implications for Pulmonary Arterial Hypertension
    Katherine Jankowski, Vineeta Jagana, Malik Bisserier, Lahouaria Hadri · 2023 · Biomedicines
  27. Histone profiles in cancer
    Simone Stefanie Riedel, Tobias Neff, Kathrin Maria Bernt · 2015 · Pharmacology & Therapeutics
  28. Epigenetic aberrations in myeloid malignancies (Review)
    Shinichiro Takahashi · 2013 · International Journal of Molecular Medicine
  29. Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms
    Anna L. Godfrey, Anthony Richard Green · 2012 · Hematology/Oncology Clinics of North America
  30. Molecular Genetics of Myelofibrosis and its associated Disease Phenotypes
    Ali Tabarroki, Ramon Velasquez Tiu · 2014 · Europe PMC (PubMed Central)
  31. Insights into the Molecular Genetics of Myeloproliferative Neoplasms
    Huong Nguyen, Jason R. Gotlib · 2012 · American Society of Clinical Oncology Educational Book
  32. Application of induced pluripotent stem cell technology for the investigation of hematological disorders
    Hamid Dolatshad, Dharamveer Tatwavedi, Doaa Ahmed, Jana F. Tegethoff, Jacqueline Boultwood, Andrea Pellagatti · 2018 · Advances in Biological Regulation
  33. Age-Related Increase of EED Expression in Early Hematopoietic Progenitor Cells is Associated with Global Increase of the Histone Modification H3K27me3
    Nina Graffmann, Jens Brands, André Görgens, Symone Vitoriano da Conceição Castro, Simeon Santourlidis, Alexandra Reckert, Inga Michele, Stefanie Ritz‐Timme, Johannes Fischer, James Adjaye et al. · 2015 · Stem Cells and Development
  34. Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes
    Anna Palau, Anne-Kathrin Garz, Jeannine Diesch, Anabel Zwick, Roberto Malinverni, Vanesa Valero, Katrina M. Lappin, Raquel Casquero, Andreas Lennartsson, Johannes A. Zuber et al. · 2017 · Oncotarget
  35. Epigenetic Therapies
    Wallace Bourgeois, Scott A. Armstrong, Emily Heikamp · 2024 · Cold Spring Harbor Perspectives in Medicine
  36. Alternative splicing of EZH2 regulated by SNRPB mediates hepatocellular carcinoma progression via BMP2 signaling pathway
    Xingyu Wang, Weiyi Liu, Chunai Zhan, Yuanyuan Zhang, Xinyu Li, Yaoyun Wang, Mengfei Sheng, Madiha Maqsood, Hang Shen, An-Min Liang et al. · 2024 · iScience
  37. Research progress on gene mutations and drug resistance in leukemia
    Xiangyu Ma, Jiamin Xu, Yanan Wang, Joshua S. Fleishman, Hao Bing, Bin Yu, Yanming Li, Letao Bo, Shaolong Zhang, Zhe‐Sheng Chen et al. · 2024 · Drug Resistance Updates
  38. EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas
    Cristian-Viktor Valea, Maurice Klein, Christian Hallermann, Hans-Joachim Schulze, Jan-Dirk Raguse, Kai Wermker · 2025 · Frontiers in Oncology
  39. Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples
    Hsiao‐Wen Kao, Hung Chang, Ming‐Chung Kuo, Jin‐Hou Wu, Ying‐Jung Huang, Ting‐Yu Huang, Tung‐Liang Lin, Lee‐Yung Shih · 2025 · Cancer
  40. Emerging role of EZH2 in solid tumor metastasis
    Ayushi Verma, Muqtada Ali Khan, Saumya Ranjan Satrusal, Dipak B. Datta · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  41. Mining the epigenetic landscape in ALL
    Lindsay M. LaFave, Ross L. Levine · 2013 · Nature Genetics
  42. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
    Somedeb Ball, Luis E. E. Aguirre, Akriti Gupta Jain, Najla E. Al Ali, Sara Tinsley, Onyee Chan, Andrew Tucker Kuykendall, Kendra Lynn Sweet, Jeffrey E. Lancet, David Andrew Sallman et al. · 2022 · Leukemia Research
  43. Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.
    Gary W. Reuther · 2011 · Europe PMC (PubMed Central)
  44. Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms
    Mandy Brecqueville, José Adélaı̈de, François Bertucci, Pascal Finetti, Max Chaffanet, Daniel Birnbaum, Anne Murati · 2012 · Cell Cycle
  45. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms
    Bhumika J. Patel, Cassandra M. Hirsch, Michael J. Clemente, Mikkael Aaron Sekeres, Hideki Makishima, Jaroslaw Pawel Maciejewski · 2015 · International Journal of Hematology
  46. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation
    Jyh‐Pyng Gau, Chih‐Cheng Chen, Yi-Sheng Chou, Chia‐Jen Liu, Yuan‐Bin Yu, Liang‐Tsai Hsiao, Liu H, Hui‐Chi Hsu, Tzeon-Jye Chiou, Po‐Min Chen et al. · 2015 · Blood Cells Molecules and Diseases
  47. Chronic lymphocytic leukemia - genomics lead the way
    Daniel Mertens, Lars Bullinger, Stephan Stilgenbauer · 2011 · Haematologica
  48. Genetic Determinants of Cancer Susceptibility
    Joe M. Angel, John DiGiovanni · 2017 · Elsevier eBooks
  49. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures
    Julian Aldana, Miranda L. Gardner, Michael A. Freitas · 2023 · International Journal of Molecular Sciences
  50. The Etiology of Acute Leukemia
    Jessica N. Nichol, Sarit E. Assouline, Wilson H. Miller · 2012 · Springer eBooks
  51. Acute Myeloid Leukemia
    Robert John Arceci, Jason N. Berman, Soheil Meshinchi · 2013 · Elsevier eBooks
  52. Mouse Models of Myeloid Malignancies
    Faisal Basheer, George S. Vassiliou · 2020 · Cold Spring Harbor Perspectives in Medicine
  53. Dominant negative effects on H3K27 methylation by Weaver syndrome-associated EZH2 variants
    Orla Deevy, Craig Monger, Francesca Matrà, Ellen Tuck, Eric Conway, Mihaly Badonyi, Darragh Nimmo, Simona Rodighiero, Qi Zhang, Chen Davidovich et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Polycomb repressive complexes as therapeutic targets in hematologic malignancies
    Makoto Yamagishi, Atsushi Iwama, Issay Kitabayashi · 2025 · Experimental Hematology
  55. Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
    David Rombaut, Sarah Sandmann, Tobias Tekath, Simon Crouch, Aniek O. de Graaf, Alexandra G. Smith, Daniel Painter, Olivier Kosmider, Magnus Tobiasson, Andreas Lennartsson et al. · 2025 · HemaSphere
  56. Au cœur d’une complexité biologique
    Myriam Koubi, Christian Chabannon, Estelle Duprez · 2017 · médecine/sciences
  57. WITHDRAWN: Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology
    Yuh Cai Chia, Marini Ramli, Peng Yeong Woon, Muhammad Farid Johan, Rosline Hassan, Md Asiful Islam · 2021 · Genes & Diseases · Retracted
  58. Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects
    Darya Chetverina, Д. В. Ломаев, Pavel G Georgiev, Maksim Erokhin · 2021 · Russian Journal of Genetics
  59. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
    Domenico Penna · 2021 · Medicina
  60. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations
    Mona Alqazzaz, Genna M. Luciani, Victoria Vu, Raquel A. C. Machado, Magdalena M. Szewczyk, Ella C. Adamson, Sehyun Cheon, Fengling Li, C.H. Arrowsmith, Mark David Minden et al. · 2023 · Experimental Hematology
  61. How I treat …
    Frank Moosig, Eva Reinhold‐Keller, Konstanze Holl‐Ulrich, Alfred Christian Feller, Thorsten Alexander Bley, Julia Ulrike Holle, Jochen Zwerina, Peter Lamprecht, Klaus Dalhoff, Nils Venhoff et al. · 2012 · Zeitschrift für Rheumatologie
  62. Clinical Predictors of Outcome in MPN
    Francesco Passamonti, Margherita Maffioli, Michele Merli, Andrea Ferrario, Domenica Caramazza · 2012 · Hematology/Oncology Clinics of North America
  63. SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis
    Giuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, Claudio Tripodo, Maria Antonella Laginestra, Simona Righi, Carlo Alberto Sagramoso Sacchetti, Anna Gazzola, Claudia Mannu, Maura Rossi et al. · 2011 · PLoS ONE
  64. Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid Leukemia (AML)
    Muhammad Tayyab · 2014 · Journal of Cancer Science & Therapy
  65. Preparation, Biochemical Analysis, and Structure Determination of SET Domain Histone Methyltransferases
    Elisa Bergamin, J.F. Couture · 2016 · Methods in enzymology on CD-ROM/Methods in enzymology
  66. Five Important Advances in Hematopathology
    Min Shi, Ruobing Xiao, Bruce A. Woda, Hongbo Yu · 2014 · Archives of Pathology & Laboratory Medicine
  67. Retinoic acid-incorporated glycol chitosan nanoparticles inhibit the expression of Ezh2 in U118 and U138 human glioma cells
    Huchen Lu, Jun Ma, Zong Zhuang, Yao Zhang, Huilin Cheng, Ji‐Xin Shi · 2015 · Molecular Medicine Reports · Retracted
  68. EVI1-Positive Leukemias and Myelodysplastic Syndromes: Theoretical and Clinical Aspects (Literature Review)
    Mamaev Nn, Alena Igorevna Shakirova, Еlena V. Morozova, Tatiana Gindina · 2021 · Clinical oncohematology
  69. Myelodysplastic Syndromes
    Christopher James Gibson, Benjamin L. Ebert, David P. Steensma · 2017 · Elsevier eBooks
  70. Tumor suppressor function of the polycomb group genes
    Makiko Mochizuki‐Kashio, George Russel Wendt, Atsushi Iwama · 2012 · Cell Cycle
  71. The role of epigenetic modifications in hematological cancers
    Jovana Ilic, Anna Bold, Stefan Tobias Knop · 2026 · Frontiers in Oncology
  72. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL–mediated leukemia
    Akihide Nakamura, Masahiro Masuya, Makoto Shinmei, Isao Tawara, Tetsuya Nosaka, Ryoichi Ono · 2024 · Blood Advances
  73. How we diagnose Myelodysplastic syndromes
    Howard S. Oster, Moshe Mittelman · 2024 · Frontiers in Oncology
  74. A novel insight of Asp193His mutation on epigenetic methyltransferase activity of human EZH2 protein: An in-silico approach
    Nisha Gautam, Satbir Kaur, Kamaljeet Kaur, Neeraj Kumar · 2019 · Meta Gene
  75. Polycomb Alterations in Acute Myeloid Leukaemia: From Structure to Function
    Teerna Bhattacharyya, Jonathan Bond · 2023 · Cancers
  76. The Heightened Importance of EZH2 in Cancer Immunotherapy
    Xiaohu Lin, Wenkai Zhou, Chengzhong Lin, Wei Cao · 2023 · Cancer Screening and Prevention
  77. Progress in the research of epigenetic regulators in cancer therapy
    Longjiang Di, Jun ZHANG, Wei‐Guo Zhu · 2023 · Scientia Sinica Vitae
  78. Mature T-cell leukemias: Molecular and Clinical Aspects
    Nathanael G. Bailey, Kojo S.J. Elenitoba‐Johnson · 2015 · Current Hematologic Malignancy Reports
  79. Retinoic acid-incorporated glycol chitosan nanoparticles inhibit the expression of Ezh2 in U118 and U138 human glioma cells
    Huchen Lu, Jun Ma, Zong Zhuang, Yao Zhang, Huilin Cheng, Ji‐Xin Shi · 2016 · Molecular Medicine Reports · Retracted
  80. Attenuated Acceleration to Leukemia after Ezh2 Loss in Nup98‐HoxD13 (NHD13) Myelodysplastic Syndrome
    Victoria Ling, Jesslyn Saw, Cedric Stevens Tremblay, Stefan Sonderegger, Emma Toulmin, Jacqueline Anne Boyle, Sung Kai Chiu, Steven Lane, Stephen B. Ting, David J. Curtis · 2019 · HemaSphere
  81. Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients
    Kaori Ito, Takahiro Hayashi, Yoko Inaguma, Tomohiko Terazawa, Maiko Ando, Yosuke Ando, Masahiro Tsuge, Azusa Kato, Akane Shimato, Shinji Suzuki et al. · 2019 · Biological and Pharmaceutical Bulletin
  82. An “EZ” Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?
    Meng Li, Ari M. Melnick · 2019 · Cancer Discovery
  83. Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms
    Naveen Pemmaraju, Natalie C. Chen, Srđan Verstovšek · 2021 · Hematology/Oncology Clinics of North America
  84. Targeting EZH2 prevents the occurrence and mitigates the development of Sjögren's syndrome in mice
    Shicong Zhu, Mei Liu, Fenglin Zhu, Xi Yu, Junsong Wen, Chengyin Li · 2022 · International Immunopharmacology
  85. In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge
    Paulina Stefaniuk, Agnieszka Szymczyk, Monika Podhorecka · 2022 · Journal of Clinical Medicine
  86. Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article
    Himanshu Singh, Magesh Kumar, Himanshu Kanungo · 2023 · Global Medical Genetics
  87. Histone H3 mutations and their impact on genome stability maintenance
    Lucas D. Caeiro, Ramiro E. Verdún, Lluís Morey · 2024 · Biochemical Society Transactions
  88. Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes
    Jing Ai, Valeria Visconte, Ali Tabarroki, Edy Hasrouni, Betty K. Hamilton, Sudipto Mukherjee, Matt E Kalaycio, Ronald M. Sobecks, Anjali S. Advani, Mikkael Aaron Sekeres et al. · 2015 · Clinical Lymphoma Myeloma & Leukemia
  89. Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia
    Stefanie Göllner, Carsten Müller‐Tidow · 2017 · Molecular & Cellular Oncology
  90. CD133 Marks a Stem Cell Population That Drives Human Primary Myelofibrosis
    Ioanna Triviai, Thomas Stübig, Birte Niebuhr, Kais Hussein, Asterios S. Tsiftsoglou, Boris Fehse, Carol Stocking, Nicolaus Martin Kröger · 2013 · Blood
  91. Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies
    Anna Maria Jankowska, Hadrian Szpurka · 2012 · Seminars in Oncology
  92. Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma
    Marta Salido, Luz Maria Martinez-Aviles, Vera Ademà, Ana Ferrer, Blanca Espinet, Mar Garcia, Antonio Salar, Carlos Besses, Lourdes Florensa, Sergi Serrano et al. · 2010 · Leukemia Research
  93. Collaboration between PcG Proteins and MLL Fusions in Leukemogenesis: An Emerging Paradigm
    Bernd B. Zeisig, Mari-Francis Arteaga, Cécile Thirant, Chi Wai Eric So · 2011 · Cancer Cell
  94. Second-Generation Sequencing for Cancer Genome Analysis
    Hye-Jung E. Chun, Jaswinder S. Khattra, Martin I. Krzywinski, Samuel A. J. R. Aparicio, Marco A. Marra · 2013 · Elsevier eBooks
  95. Genetically altered cancer epigenome
    Ming Tang, Huacheng Luo, Jianrong Lu · 2015 · Elsevier eBooks
  96. The Etiology of Acute Leukemia
    Jessica N. Nichol, Mena Kinal, Wilson H. Miller · 2017 · Springer eBooks
  97. BCR-ABL1 -Negative Chronic Myeloid Neoplasms: An Update on Management Techniques
    Alessandro Maria Vannucchi, Lisa Pieri, Maria Chiara Susini, Paola Guglielmelli · 2012 · Future Oncology
  98. Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders
    Andreas Hochhaus, Andreas Reiter, Thomas Ernst, Paul Graf La Rosée · 2012 · Onkologie
  99. Update on JAK2 inhibitors in myeloproliferative neoplasm
    Daniel Chan, Maya Koren‐Michowitz · 2011 · Therapeutic Advances in Hematology
  100. Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms
    Simona Stivala, Sara C. Meyer · 2021 · Cancers